Vardenafil

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Levitra, Vivanza; Belgium: Levitra; Czech Republic: Levitra, Vivanza; Denmark: Levitra; Estonia: Levitra, Vivanza; Finland: Levitra; France: Levitra; Germany: Levitra, Vivanza; Greece: Levitra, Vivanza; Hungary: Levitra, Vivanza; Ireland: Levitra, Vivanza; Italy: Levitra, Vivanza; Latvia: Levitra, Vivanza; Lithuania: Levitra, Vivanza; Luxembourg: Levitra, Vivanza; Netherlands: Levitra, Vivanza; Poland: Levitra, Vivanza; Portugal: Levitra, Vivanza; Romania: Levitra, Vivanza; Slovakia: Levitra, Vivanza; Spain: Levitra; Sweden: Levitra, Vivanza; UK: Levitra.

North America

Canada: Levitra; USA: Levitra, Staxyn.

Latin America

Argentina: Levitra; Brazil: Levitra, Vivanza; Mexico: Levitra.

Asia

Japan: Levitra.

Drug combinations

Chemistry

Vardenafil Dihydrochloride: C~23~H~32~N~6~O~4~S 2HCl. Mw: 561.52. Piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-, dihydrochloride. CAS-224789-15-5 (2001).

Pharmacologic Category

Vasodilating Agents; Phosphodiesterase Inhibitors. Phosphodiesterase-5 Enzyme Inhibitor. (ATC-Code: G04BE09).

Mechanism of action

Affects response to sexual stimulation. When sexual stimulation causes local release of nitric oxide, inhibition of PDE-5 by vardenafil causes increased levels of cGMP in corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to corpus cavernosum.

Therapeutic use

Treatment of erectile dysfunction.

Pregnancy and lactiation implications

Teratogenic effects not observed in animal studies. Not indicated for use in women. Excretion in breast milk unknown.

Unlabeled use

Contraindications

Hypersensitivity to vardenafil or any component of the formulation. Concurrent (regular or intermittent) use of organic nitrates in any form (e.g. nitroglycerin, isosorbide dinitrate).

Warnings and precautions

May cause dose-related impairment of color discrimination. Use caution in retinitis pigmentosa (a minority of patients have genetic disorders of retinal phosphodiesterases). Sudden decrease or loss of hearing reported rarely; may be accompanied by tinnitus and dizziness. Hypotension may occur due to vasodilator effects (use with caution in aortic stenosis or hypertrophic obstructive cardiomyopathy). Concurrent use with α-adrenergic antagonist therapy may cause symptomatic hypotension. Rarely, priapism reported (use with caution in conditions which may predispose patients to priapism (sickle cell anemia, multiple myeloma, leukemia)). Vision loss may occur rarely and be a sign of nonarteritic anterior ischemic optic neuropathy (risk may be increased with history of vision loss, low cup-to-disc ratio («crowded disc»), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and >50 years of age). Use not recommended in degenerative retinal disorders (e.g. retinitis pigmentosa). Use with caution in anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie’s disease). Use with caution in bleeding disorders. Use not recommended in hypotension (<90/50 mm Hg), uncontrolled hypertension (>170/100 mm Hg), unstable angina or angina during intercourse, life-threatening arrhythmias, stroke or myocardial infarct within last 6 months, cardiac failure or coronary artery disease causing unstable angina. Use caution in left ventricular outflow obstruction (e.g. aortic stenosis). Not recommended for use in congenital QT prolongation. Use with caution in hepatic impairment (use not recommended in severe hepatic impairment), and in active peptic ulcer disease. Use in end-stage renal disease requiring dialysis not recommended. Use with caution in patients taking α-blockers (may cause hypotension) or medications known to prolong QT interval. Avoid use in patients taking class Ia or III antiarrhythmics. High potential for CYP-mediated interactions (use with caution in patients taking strong CYP3A4 inhibitors). Concomitant use with all forms of nitrates contraindicated. Concurrent use with other treatments for erectile dysfunction not recommended. Use with caution in the elderly.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart